メインコンテンツに移動

Laying the foundations

India's embryonic structured products market is poised for takeoff, although it is currently governed by a set of restrictive regulations that prevent the use of over-the-counter derivatives and certain derivative instruments. Are the regulations anathema or just a necessary step towards a flourishing structured products market? Matt Cameron reports

The liberalisation of regulations concerning derivatives and structured products in India has proceeded at a moderate pace. Regulators have refused to bow to market pressure to relax their rules, and have instead implemented austere measures that they hope will protect investors and act as a tool to enhance market competition. Some market participants regard the process as overly protracted, while

コンテンツを印刷またはコピーできるのは、有料の購読契約を結んでいるユーザー、または法人購読契約の一員であるユーザーのみです。

これらのオプションやその他の購読特典を利用するには、info@risk.net にお問い合わせいただくか、こちらの購読オプションをご覧ください: http://subscriptions.risk.net/subscribe

現在、このコンテンツをコピーすることはできません。詳しくはinfo@risk.netまでお問い合わせください。

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Risk.net? View our subscription options

無料メンバーシップの内容をお知りになりたいですか?ここをクリック

パスワードを表示
パスワードを非表示にする

Most read articles loading...

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

ログイン
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here